Abstract: The present invention relates to a new process for the preparation of compounds of the formulae and their pharmaceutically acceptable acid addition salts, which are NMDA (N-methyl-D-aspartate)-receptor-subtype selective blockers.

Abstract: The present invention relates to a new process for the preparation of compounds of the formulae 1

Abstract: Amino-amide ruthenium complexes of the general formula RuH(L′{—H})(Y) and RuX(L′{—H})(Y) wherein X signifies chlorine, bromine or iodine, Y signifies a neutral ligand, L′ signifies a monosulphonylated diamine of the general formula R1SO2—HN—CH2—(CH2)n—CH2—NHR4  II′ R1 signifies optionally mono- or multiply fluorinated alkyl, alkenyl, alkynyl, cycloalkyl, optionally mono- or multiply-substituted aryl, heteroaryl or camphor-10-yl, R4 signifies hydrogen or alkyl, and n signifies 0, 1, 2 or 3. is described.

Abstract: A process for the manufacture of trans-(R,R)-actinol by diasteroselective transfer hydrogenation of levodione comprises hydrogenating (R)-levodione in the presence of a hydrogen donor, which simultaneously can be used as the solvent, and an amino-amide-ruthenium complex, especially of the formula RuH(L{—H})(Y), wherein Y signifies a neutral ligand and L signifies an optionally optically active monosulphonylated diamine ligand, as defined in more detail in the description. Moreover, the invention is concerned with some of the amino-amide-ruthenium complexes and with the corresponding precursors to these complexes, which have halogen in place of H. The product of the process in accordance with the invention, trans-(R,R)-actinol, is known as an important building block for the synthesis of carotenoids, e.g. zeaxanthin. By the process trans-(R,R)-actinol is made available in particularly high enantiomeric and diasteromeric purity.

Abstract: Optically active .alpha.-bromo- or .alpha.-chlorocarboxylic compounds of the formula ##STR1## wherein X is bromine or chlorine;M is hydrogen, NR.sub.4.sup.+1 or a cation of an alkali or alkaline earth metal;R.sup.1 is hydrogen or lower alkyl;n is 0 or 1;R is hydrogen, C.sub.1 -C.sub.20 alkyl, or C.sub.1 -C.sub.20 alkyl substituted in the terminal position with --NR.sup.2.sub.2, --COOR.sup.2, --OR.sup.3, a free or protected --CHO group or a ring A;R.sup.2 is hydrogen or a lower alkyl;R.sup.3 is hydrogen or a protecting group;ring A is an unsubstituted or substituted ring; and* is a center of chirality,are prepared by enantioselectively hydrogenating, in the presence of a ruthenium complex of an optically active diphosphine ligand, a (Z)-.alpha.,.beta.-unsaturated compound of the general formula ##STR2## wherein R, n, X and M are as defined above.

Abstract: A process for the asymmetric hydrogenation of a compound of the formula ##STR1## wherein each R, independently, is alkyl, arylmethyl, aryl, alkoxy, arylmethoxy or aryloxy or both R's, taken together, are methylene, ethylene or 1,2-phenylene and n is 1,2 or 3,or of a salt thereof to a compound of the formula ##STR2## in the form of an (S) or (R) enantiomer, wherein R and n have the significances given above, using an optically active ruthenium-diphosphine complex as catalyst, is described. The preparation of the compounds of formula II, as well as the compounds of formula II, which form a further object of the invention, are also described.

Abstract: The present invention is concerned with a process for the manufacture of optically active compounds of the formula ##STR1## wherein R signifies lower alkyl, lower alkoxy, phenyl, benzyl or --NR.sub.2.sup.1, R.sup.1 signifies lower alkyl, phenyl, benzyl or hydrogen and * signifies an optically active center, by asymmetrically hydrogenating an enol derivative of ketoisophorone of the formula ##STR2## wherein R has the significance given above, in the presence of a rhodium complex of an optically active diphosphine ligand.

Abstract: There is disclosed a process for the asymmetrical hydrogenation of (E)-2-methyl-3-phenyl-2-propen-1-ol of formula ##STR1## wherein R.sub.1 is as defined herein, to give compounds of formula ##STR2## The catalyst is a neutral or cationic rhodium complex of a chiral atropisomeric phosphine.

Abstract: The present invention describes novel chiral rhodium-diphosphine complexes having the formula[Rh(X) (Y) (Lp)]owherein X represents a residue of the formula X--COO.sup.- in which Z signifies a group ##STR1## aryl or substituted aryl, wherein R.sup.1, R.sup.2, R.sup.3 =hydrogen, halogen, lower alkyl, aryl-lower alkyl, perfluoro-C.sub.1-20 -alkyl, aryl, substituted aryl, the group --OR.sup.7, --(CH.sub.2).sub.m --COA or AOC--(CF.sub.2).sub.n, with the proviso that at least one of R.sup.1, R.sup.2, and R.sup.3 represents --OR.sup.7, aryl or substituted aryl,R.sup.4, R.sup.5, R.sup.6 =hydrogen, halogen, lower alkyl, aryl-lower alkyl, perfluoro--C.sub.1-20 -alkyl, aryl, substituted aryl, --(CH.sub.2).sub.m --COA or AOC--(CF.sub.2).sub.n,R.sup.7 =hydrogen, lower alkyl, partially or completely halogenated lower alkyl, aryl, substituted aryl or aryl-lower alkyl,A=The residue --OR or NR'.sub.

Abstract: The invention is concerned with novel isoquinoline derivatives of the formula ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl-lower alkyl or aryl-lower alkoxy andR.sup.2 is phenyl or substituted phenyl.These novel isoquinoline derivatives are valuable intermediates in the manufacture of morphinan derivatives.

Abstract: There are described novel chiral rhodium-diphosphine complexes of the formula[Rh (X) (Y) (L.sub.0,1,2)].sub.1,2 Iwherein X, which may be fixed to a carrier, is Z--COO.sup.-, wherein Z is ##STR1## perfluorophenyl, perfluorobiphenyl or a residue of the formula ##STR2## and R.sup.1, R.sup.2 and R.sup.3 is halogen, lower alkyl, perfluorophenyl, perfluoro-C.sub.1-20 -alkyl, hydrogen or the group --COA or AOC--(CF.sub.2).sub.n -- in which A is --OR or --NR'.sub.2, except that at least one of the substituents R.sup.1, R.sup.2 and R.sup.3 is fluorine, R is hydrogen, lower alkyl or a cation, R' is hydrogen or lower alkyl and n is 1 to 20 and wherein Y is a chiral diphosphine ligand and L is a neutral ligand.

Abstract: Novel chiral phosphines are disclosed which when complexed with rhodium provide catalyst compositions for asymmetric hydrogenations.

Abstract: Novel chiral phosphines are disclosed which when complexed with rhodium provide catalyst compositions for asymmetric hydrogenations.

Abstract: There is disclosed a novel process for preparing a number of cinnamaldehyde derivatives. These cinnamaldehyde derivatives can be reduced to dihydrocinnamaldehyde derivatives, a number of which are commercially important in the preparation of fragrances. The invention is also directed to a number of novel intermediates and their preparation.

Abstract: There is disclosed a novel process for preparing a number of cinnamaldehyde derivatives. These cinnamaldehyde derivatives can be reduced to dihydrocinnamaldehyde derivatives, a number of which are commercially important in the preparation of fragrances. The invention is also directed to a number of novel intermediates and their preparation.

Abstract: The compound 6-hydroxy-3-(5-hydroxy-3-methyl-1,3-pentadienyl)-2,4,4-trimethyl-2-cyclohe xen-1-one useful as intermediate for producing the natural coloring agent astaxanthin as well as a method for synthesizing astaxanthin from this compound and synthesizing the compound from 2-hydroxyketo isophorone.